MCK240920P660000
- 100.00
- 0.000.00%
McKesson Newsroom
Why McKesson (MCK) Is a Top Value Stock for the Long-Term
McKesson (MCK) Exceeds Market Returns: Some Facts to Consider
Wells Fargo Maintains Equal-Weight on McKesson, Lowers Price Target to $535
Investors in McKesson (NYSE:MCK) Have Seen Splendid Returns of 264% Over the Past Five Years
Deutsche Bank Trims Price Target on McKesson to $623 From $631
Leerink Partners Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $665
Leerink Partners analyst Michael Cherny maintains $McKesson(MCK.US)$ with a buy rating, and maintains the target price at $665.According to TipRanks data, the analyst has a success rate of 50.0% and
Michael Cherny Reaffirms Buy Rating on McKesson Amid Temporary Setbacks and Long-Term Growth Prospects
Wells Fargo Maintains McKesson(MCK.US) With Hold Rating, Cuts Target Price to $535
Wells Fargo analyst Steve Baxter maintains $McKesson(MCK.US)$ with a hold rating, and adjusts the target price from $576 to $535.According to TipRanks data, the analyst has a success rate of 54.7%
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), McKesson (MCK) and Neurocrine (NBIX)
Is McKesson Stock Underperforming the S&P 500?
McKesson Corporation (MCK) Is Attracting Investor Attention: Here Is What You Should Know
McKesson Corporation's (NYSE:MCK) Institutional Investors Lost 11% Last Week but Have Benefitted From Longer-term Gains
Here's How Much You Would Have Made Owning McKesson Stock In The Last 20 Years
McKesson Is Maintained at Buy by Citigroup
McKesson Analyst Ratings
Jefferies Adjusts Price Target on McKesson to $607 From $630
Citi Maintains McKesson(MCK.US) With Buy Rating, Cuts Target Price to $630
Citi analyst Daniel Grosslight maintains $McKesson(MCK.US)$ with a buy rating, and adjusts the target price from $670 to $630.According to TipRanks data, the analyst has a success rate of 50.0% and
Express News | Mckesson Corp : Citigroup Cuts Target Price to $630 From $670
Biologics by McKesson's RYTELOTM, FDA Gets Approval For Treatment Of Patients With Low- To Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia
McKesson, News Corporation And 2 Other Stocks Executives Are Selling